Is Galmed Pharmaceuticals Ltd. (GLMD) a Buy, Sell, or Hold?
Galmed Pharmaceuticals Ltd.
NASDAQ:GLMD
$0.5135 USD
$0.0 (0.43%)
- Volume
- 20.08K
- Average Volume
- 544.06K
- Market Capitalization
- $2.81M
- P/E Ratio
- -0.26
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $2.34
- Year Low
- $0.41
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.71
| Source | Headline |
|---|---|
|
Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd.
Colospan Ltd. ("Colospan") provides Galmed Pharmaceuticals Ltd. prnewswire.com - 2026-06-22 07:00:00 |
|
Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market
Transaction will add FDA Breakthrough Device-Designated technology with active U.S. pivotal IDE trial, positioning Galmed to address one of colorectal surgery's most serious unmet needs. Colospan's CG-100 Intraluminal Bypass Device, is CE marked under EU's Medical Device Regulation ("MDR") and ready for commercial launch in the EU and Israel. prnewswire.com - 2026-06-08 08:10:00 |
|
Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis
- Tissue Dynamics identified a previously unrecognized metabolic mechanism driving cardiac fibrosis using a human cardiac organoid model, revealing disease biology that is not accessible through conventional animal models. - In inflammatory human cardiac organoids, the combination of Aramchol Meglumine and a selective PPARα agonist reduced fibrotic burden by approximately 4-fold (p prnewswire.com - 2026-06-02 07:30:00 |
|
Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg
Results from Study AM-001 mark a pivotal advance through the transition to a once daily lower 400mg dose of AM enabling: Production of GMP clinical batch for Galmed's upcoming clinical trials Solidification and prolongation of Aramchol's IP protection Potential reduction in drug CoGs by ~50% Improvement in patients' convenience and compliance upon potential commercialization RAMAT-GAN, Israel, May 14, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, announced today major milestone results from a Phase 1 PK study in healthy subjects (Study AM-001). prnewswire.com - 2026-05-14 07:30:00 |
|
Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics
Novel vascularized, sensor-embedded cardiac organoid model will focus on chronic post-MI remodeling and HFpEF, linking lipid metabolism, SCD1 activity, fibrosis, and impaired tissue repair REHOVOT, Israel and RAMAT-GAN, Israel, May 6, 2026 /PRNewswire/ -- Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. prnewswire.com - 2026-05-06 07:30:00 |
|
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Update
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD - Get Free Report) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 502,390 shares, a growth of 2,578.7% from the March 31st total of 18,755 shares. Approximately 11.4% of the company's shares are short sold. defenseworld.net - 2026-04-25 02:38:52 |
